Rapid Action Drug Alerts and Response (RADAR) Alerts
Nitazenes alert 2023

Printable summaries of this alert

• The unregulated drug supply is increasingly toxic and unpredictable. Getting into drug treatment reduces the risk of experiencing harm or dying from an overdose. Click here to find a drug service in your area.
• There are ways to reduce the risk of harm and overdose when taking drugs, but there is no safe way to take nitazenes. Even when following all harm reduction advice, there is still a significant risk involved in taking them.
• Due to their potency, it’s almost impossible to accurately measure the right dose. The contents in a single pill can vary widely even within the same batch.
• If you buy tablets that are of poor quality or crumble easily, this may be an indicator that they have been illicitly produced. Be aware that even if a tablet looks authentic, it may be fake and it can be difficult to distinguish between genuine and counterfeit medication.
• Any medicine obtained without a prescription should be treated with caution.

PHS strongly recommends people do not take oxycodone tablets from any source unless they have been prescribed to them.

Although many nitazene detections have been in drugs sold as oxycodone, there is a risk these drugs may appear in the wider drugs supply and be sold as something else. Great caution is advised. Everyone taking drugs – not just oxycodone or other opioids – should be aware of the information below.

High-risk settings are places where people may take more drugs than average, often at the same time and from shared batches. Places at higher risk include prisons, hostels, supported accommodation, nightlife venues, festivals, care homes and educational settings.

People living and working in these settings should:

• Ensure their setting is prepared and ready to respond to overdose situations.
• Be vigilant to opioid use and aware of the signs of an overdose. Encourage people to report overdose signs immediately. In an emergency, stay calm and call 999 straight away.
• Carry and promote naloxone.
• Ensure the setting has multiple naloxone kits available and trained people able to respond.
• Check that kits have not expired and that they are easy to access in the event of an emergency.
• Provide regular refresher training on drug-related emergencies, including information on risk factors, identifying an overdose, basic life support and how to administer naloxone.

To arrange naloxone training for your service, speak to your local Alcohol and Drug Partnership or visit the SDF webpage on take-home naloxone training.

• When asking patients about substance use, also enquire about any potential use of oxycodone or other pain-relief medicines. Oxycodone may be referred to by brand names such as OxyContin and Percocet, or street names such as ‘oxy’ and ‘30s’.
• Use the opportunity to raise awareness on the risks of taking counterfeit medication.
• Discuss harm reduction approaches including the risk of mixing drugs and the importance of drug checking.
• Service staff can help people access the drug testing service WEDINOS. Staff should not handle any substances but can facilitate service access by providing printed sample submission forms, stamped addressed envelopes and by sharing online results.
• Share reminders of the signs of an overdose and the importance of getting help in an emergency.
• Provide people with naloxone and offer regular refresher training for those previously trained.
• Services and Alcohol and Drug Partnerships should share this alert with local partners who are likely to be in contact with people who take drugs.

All staff working in emergency services and healthcare should be vigilant for the presentation of patients with opioid toxicity:

• decreased respiration
• decreased pulse
• decreased mental activity
• decreased pupil size (miosis)
• decreased blood pressure
• decreased temperature
• decreased gastrointestinal motility

A progression of signs and symptoms includes drowsiness with eventual pin-point pupils, loss of consciousness, airway compromise and respiratory arrest, which can be rapidly fatal if untreated.

Build links with your local drug services and liaison team and encourage patients to access support and take-home naloxone wherever the opportunity presents.

All organisations that provide emergency care for opioid overdose should ensure staff are able to:

• Treat suspected cases as for any opioid overdose, using naloxone and appropriate supportive care (including airway and breathing support).
• Recognise that the duration of effect of naloxone is shorter than that of opioid drugs and appropriate monitoring and further doses of naloxone may be required.
• In the community this could include injectable or intranasal naloxone. Doses should be administered one at a time, waiting 2–3 minutes between each dose while watching for a response.

In specialist medical settings only

• Where hospital-based toxicology services are available, physicians are encouraged to submit specimens of unusual opioid toxidromes to ascertain the presence of nitazene compounds.
• Treatment may involve the intravenous naloxone titration regimen recommended by the National Poisons Information Service (see below).

Naloxone dosing in acute medical care

For adults and children aged 12 years or over, in acute hospitals the standard naloxone dosing regimen where potent opioid overdose is suspected, subject to clinical assessment of the individual case, is:

• Give an initial dose of 400 micrograms (0.4 mg) intravenously (IV).
• If there’s no response after 60 seconds, give a further 800 micrograms (0.8 mg).
• If there’s still no response after another 60 seconds, give another 800 micrograms (0.8 mg).
• If still no response, give a further 2 mg dose. Large doses (more than 4 mg) may be required in patients exposed to highly potent opioids and those who are severely poisoned.
• Aim for reversal of respiratory depression and maintenance of airway protective reflexes, not full reversal of unconsciousness.
• Failure of a definite opioid overdose to respond to large doses of naloxone suggests that another central nervous system (CNS) depressant drug or brain damage is present.
• Once an adequate response has occurred, monitor blood gases, oxygen saturation and respiratory rate.
• Intramuscular naloxone is an alternative in the event that IV access is not possible or is delayed.
• Observe the patient carefully for recurrence of CNS and respiratory depression. The duration of action of naloxone is shorter than that of all opioid analgesics and repeated doses of naloxone may be required.

For further advice, medical professionals can use the National Poisons Information Service 24-hour telephone service on 0344 892 0111 or its online database, TOXBASE.

In March 2024, 15 new opioids were added to the Misuse of Drugs Act 1971.

Now most nitazenes (including protonitazene, metonitazene, isotonitazene and n-pyrrolidino etonitazene) are classified as class A drugs.

• For more information on nitazenes, read this briefing from the Advisory Council on the Misuse of Drugs.
• For more information on opioid overdose, visit Stop the Deaths.
• For help and support or information on drugs, visit NHS inform.
• To order naloxone, visit Scottish Families Affected by Drugs and Alcohol: Take Home Naloxone.
• To make a report use our reporting form or email phs.drugsradar@phs.scot